Achieve Life Sciences, Inc. — Q1 2024 Form 10-Q
Business context and reporting period
Clinical-stage pharmaceutical company developing cytisinicline for smoking cessation and nicotine addiction. This unaudited report covers the three months ended March 31, 2024; the comparable period is Q1 2023. The company has no approved products and has generated no product revenue.
Key financial metrics
Amounts below are in millions of U.S. dollars, except per-share data and percentages.
| Metric | Q1 2024 / March 31, 2024 | Comparable / December 31, 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $2.8 | $5.5 in Q1 2023 |
| General and administrative expense | $3.2 | $3.0 in Q1 2023 |
| Net loss | $6.5; $0.26 per share | $9.0; $0.50 per share in Q1 2023 |
| Net cash used in operations | $5.3 | $8.3 in Q1 2023 |
| Cash and cash equivalents | $66.4 | $15.5 |
| Working capital | $47.1 | Not stated for December 31, 2023 |
| Convertible debt carrying value | $17.1; $15.0 principal | $16.7 carrying value |
| Accumulated deficit | $172.2 | $165.8 |
Gross margin is not applicable because the company has no product sales. No operating cash-flow margin is reported.
Material changes versus the prior comparable period
- Operating expenses fell 30%, mainly because Phase 3 ORCA-3 and Phase 2 ORCA-V1 trials were completed in Q2 2023; Q1 2024 R&D costs included ORCA-OL planning.
- Net loss narrowed by $2.5 million, while operating cash use declined by $3.0 million.
- Q1 2024 financing provided $56.1 million net from a February registered direct offering. The offering issued 13.1 million common shares and included warrants for up to 13.1 million additional shares.
- Common shares outstanding increased from 21.2 million at December 31, 2023 to 34.3 million at March 31, 2024. The February warrants and other equity awards create further potential dilution.
- Interest expense rose to $0.8 million from $0.6 million; higher interest income partly offset the increase in other expense.
Outlook, risks and unusual items
- Management expects existing cash to fund current operating expenses and capital expenditures into the second half of 2025, including a potential NDA submission and potential debt repayment. The company nevertheless has no operating revenue and expects continuing losses and substantial future spending.
- Following FDA discussions, the company says a single open-label long-term safety study, ORCA-OL, will satisfy the additional safety-data requirement for an NDA submission. It planned to start the study in Q2 2024, enroll up to 650 prior ORCA-program participants, and monitor safety for up to one year. The NDA submission is anticipated in the first half of 2025. FDA acceptance and approval are not assured.
- The debt agreement has a stated maturity of December 22, 2024, but may accelerate to August 1, 2024 if the FDA has not accepted the smoking-cessation NDA for filing by July 31, 2024; specified filing deficiencies could result in an August 15 maturity. Timely NDA submission by June 30 could extend these trigger dates by one month. Management said it expects August 1 maturity absent a waiver or renegotiation. A February term sheet for an extension is non-binding, and no definitive agreement is assured.
- The loan bears cash interest at a floating rate tied to prime, plus 7% annual paid-in-kind interest compounded monthly; the debt is secured by substantially all assets other than intellectual property. Failure to refinance or repay could create default and enforcement risk.
- Key business risks include dependence on cytisinicline as the sole product candidate; reliance on Sopharma as the sole current manufacturer and supplier; regulatory, clinical, supply-chain and impurity risks; and the need for future financing. Cash is concentrated at financial institutions, and debt covenants require substantially all cash and investments to be held with SVB.
- Management reported disclosure controls and procedures were effective at quarter-end, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether ORCA-OL began on schedule, recruitment and safety results, and whether FDA maintains the stated data requirements and NDA timing.
- Whether the lenders executed a binding maturity extension or waiver, and the actual debt maturity, repayment, conversion and interest obligations.
- Cash burn and runway relative to management’s second-half 2025 estimate, including expected ORCA-OL, regulatory, manufacturing and debt-related costs.
- Potential dilution from the 13.1 million February warrants, other outstanding warrants and equity awards, and any subsequent share issuance.
- Sopharma’s ability to supply cytisinicline and satisfy quality and regulatory requirements, including any FDA inspection or impurity findings.